# Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

> **NCT02833142** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 28 (actual)

## Conditions studied

- Multiple Sclerosis
- Acute Optic Neuritis

## Interventions

- **DRUG:** BIIB033 (opicinumab)

## Key facts

- **NCT ID:** NCT02833142
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833142, "Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02833142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*